In 2007, infliximab (IFX), an anti-TNF-α monoclonal antibody, was approved in Japan for the treatment of BD-associated refractory retinitis/uveitis, on the basis of the results of a clinical study.[9] Available data on the efficacy of IFX in intestinal BD, NBD, and VBD have been obtained mainly from case studies and retrospective cohort clinical studies,[10–17] and only rarely from prospective clinical studies. The gene discussed is TNF; the disease is Behcet disease.